Fifty-seven infants exposed to phencyclidine (PCP) in utero were followed for the first year of life. Thirty-six (65%) of the 55 for whom birth records were available manifested symptoms of neonatal narcotic withdrawal syndrome, including 16 (52%) of those whose mothers denied opiate abuse during pregnancy. Temperament problems were noted in 47% of the babies and sleep problems in 14%. The majority of infants grew normally, but a larger than expected number started out small and remained small. Testing using the Bayley Scales of Infant Development at age one year revealed a mental development index (mean +/- SD) of 94 +/- 10 and a psychomotor development index of 98 +/- 10. Attachment behavior was abnormal in 17%. Most infants were cared for by their natural mother. Further studies are needed to determine later effects of in utero PCP exposure, as well as effects on the infants being raised by women who have used PCP. Phencyclidine toxicity needs to be considered when evaluating babies with signs of neonatal narcotic withdrawal syndrome.

Download full-text PDF

Source
http://dx.doi.org/10.3109/00952998908993397DOI Listing

Publication Analysis

Top Keywords

exposed phencyclidine
8
phencyclidine pcp
8
neonatal narcotic
8
narcotic withdrawal
8
withdrawal syndrome
8
development +/-
8
babies exposed
4
pcp
4
pcp utero?
4
utero? fifty-seven
4

Similar Publications

Article Synopsis
  • * Researchers investigated changes in GABAergic interneuron populations and inflammatory markers in the rats' brains, finding significant reductions in GABA markers like parvalbumin and increased activation of microglia in the PCP-Iso group compared to those with single-hit isolation.
  • * These results support the use of the PCP-Iso model for future research into treatments aimed at correcting excitatory-inhibitory balance and addressing neuroinflammation related to schizophrenia.
View Article and Find Full Text PDF

Role of cyclin-dependent kinase 5 in psychosis and the modulatory effects of cannabinoids.

Neurobiol Dis

January 2023

Integrative Pharmacology and Systems Neuroscience, Neuroscience Research Program, IMIM-Hospital del Mar Research Institute, Barcelona, Spain; Department of Medicine and Life Sciences, University Pompeu Fabra, Barcelona, Spain. Electronic address:

Cyclin-dependent kinase 5 (CDK5) is a serine/threonine kinase that has emerged as a key regulator of neurotransmission in complex cognitive processes. Its expression is altered in treated schizophrenia patients, and cannabinoids modulate CDK5 levels in the brain of rodents. However, the role of this kinase, and its interaction with cannabis use in first-episode psychosis (FEP) patients is still not known.

View Article and Find Full Text PDF

Adolescent nicotine potentiates the inhibitory effect of raclopride, a DR antagonist, on phencyclidine-sensitized psychotic-like behavior in mice.

Toxicol Appl Pharmacol

December 2022

Laboratório de Neurofisiologia, Departamento de Ciências Fisiológicas, Instituto de Biologia Roberto Alcantara Gomes, Universidade do Estado do Rio de Janeiro (UERJ), Rio de Janeiro, RJ, Brazil. Electronic address:

Article Synopsis
  • * It finds that nicotine does not worsen psychotic-like behavior induced by phencyclidine and might actually help reduce these behaviors under certain conditions, specifically when combined with raclopride, a drug that targets dopamine receptors.
  • * Overall, the results suggest that nicotine may improve the effectiveness of treatments for psychotic symptoms by influencing dopamine receptor activity, rather than exacerbating psychotic behaviors in adolescent mice.
View Article and Find Full Text PDF

Maternal drug use during pregnancy is a significant concern. Drug-exposed newborns are often born premature and may suffer from birth defects, neonatal abstinence syndrome and cognitive and developmental delays. Because of this, testing of neonatal specimens is carried out to assess fetal drug exposure during pregnancy.

View Article and Find Full Text PDF

The lack of translation from basic research into new medicines is a major challenge in CNS drug development. The need to use novel approaches relying on (i) patient clustering based on neurobiology irrespective to symptomatology and (ii) quantitative biomarkers focusing on evolutionarily preserved neurobiological systems allowing back-translation from clinical to nonclinical research has been highlighted. Here we sought to evaluate the mismatch negativity (MMN) response in schizophrenic (SZ) patients, Alzheimer's disease (AD) patients, and age-matched healthy controls.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!